Skip to main content
. 2024 Jan 8;14:1339337. doi: 10.3389/fimmu.2023.1339337

Table 3.

Treatment response to anti-IL1 drugs in PAMI syndrome.

ID article (IDPatient)/Cycles Syndrome DRUG/DOSE-duration Previous treatment Concomitant treatment Clinical efficacy Efficacy
6-12 weeks/12-24 weeks/>24 weeks/
Adverse events/Recurrence
Acne PG PA
21 (5)/1 PAMI Canakinumab 300mg every 4 weeks Prednisolone, topical tacrolimus, infliximab, Secukinumab, prednisone and isotretinoin Corticosteroids, cyclosporine NA NA NA No NA
3 months No NA
NA
23 (6)/1 PAMI NA NA NA NA NA NA NA NA
   
31 (8)/1 PAMI Anakinra Infliximab, tocilizumab, HD IVIG, corticosteroids, ruxolitinib, rituximab, cyclophosphamide NA NA NA NA
31 (9)/1 PAMI Anakinra NA NA NA NA
31 (9)/1 Canakinumab NA NA NA NA
31 (10)/1 PAMI Anakinra Etanercept, infliximab, corticosteroids NA NA NA NA
33 (11)/1 PAMI Canakinumab 2mg/kg/month and 4mg/kg/month Antibiotics, corticosteroids, IVIG, colchicine, Cyclosporine NA Yes (c) Yes No
Yes No
Yes (2 years)
34 (12)/1 PAMI Anakinra Intra-articular steroids inyections, antibiotics, adalimumab, colchicine NA Yes (c) Yes (c) NA Yes NA
2 year NA NA
NA Poor compliance
34 (12)/2 Canakinumab Intra-articular steroids inyections, antibiotics, adalimumab, colchicine, anakinra Corticosteroids Yes (p) Yes (p) NA Yes Proteinuria
Yes Flares of acne and PG
Yes
34 (12)/3 Canakinumab 150mg monthly Intra-articular steroids inyections, antibiotics, adalimumab, colchicine, anakinra, corticosteroids, tacrolimus Tacrolimus Yes (p) Yes (p) NA Yes NA
1 year Corticosteroids Yes NA
Yes
35 (13)/1 PAMI Anakinra 3mg/kg once daily NA NA NA NA NA Yes Mild transient urticarial skin reaction at the injection site
6 months Yes No
Yes (6 months)

PA, pyogenic arthritis; A, acne; PG, pyoderma gangrenosusm; NA, not available; -, not applicable; NSAID, Non-steroidal anti-inflammatory drugs; c, complete (dark green colour); p, partial (green light colour). Partial (p) and Complete (c ). Response to treatment are terms defined by the original studies.